Pharmacodynamics and Pharmacokinetics of AM103, a Novel Inhibitor of 5-Lipoxygenase-Activating Protein (FLAP)

Leukotriene E4–induced pulmonary inflammation is mediated by the P2Y12receptor

(2009) Sailaja Paruchuri et al.   JOURNAL OF EXPERIMENTAL MEDICINE

5-Lipoxygenase-Activating Protein Inhibitors: Development of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103)

(2009) John H. Hutchinson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pharmacological Characterization of 3-[3-tert-Butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic Acid (AM103), a Novel Selective 5-Lipoxygenase-Activating Protein Inhibitor That Reduces Acute and Chronic Inflammation

(2009) D. S. Lorrain et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

The role ofLTA4HandALOX5APpolymorphism in asthma and allergy susceptibility

(2008) J. W. Holloway et al.   ALLERGY

Leukotriene Signaling in Atherosclerosis and Ischemia

(2008) Magnus Bäck   CARDIOVASCULAR DRUGS AND THERAPY

What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases

(2008) J EVANS et al.   TRENDS IN PHARMACOLOGICAL SCIENCES